RE: Long way to go12 Feb 2026 08:59
Operational highlights • Synergistic acquisitions of two Clinical Research Units from CRS and Cryostore completed for £10.5 million net of cash acquired • Integration near completion and sales synergies being realised • Strong progress with Clinical Services and hLAB services - completed delivery of 817 participant Phase II influenza trial • £3.2 million hLAB contract signed for an international, multi-site Phase II field trial • £5.5 million CRS contracts signed in the period, the majority of which will be recognised in 2025 • Letter of Intent (“LOI”) signed with ILiAD Biotechnologies (“ILiAD”) for world’s first pivotal Phase III human challenge trial (“HCT”) which is expected to be the Group’s largest HCT to date • Bacterial lab fit-out completed ahead of future bacterial HCTs and hLAB contracts